One Intervention Led to a 91% Reduction in Breast Nodules: Inybrain tiNK Demonstrates Breakthrough Clinical Results

For most women, seeing the term “breast nodules” on a physical examination report brings intense psychological stress and panic.

According to the 2025 China Women’s Health Pink Report, among women who underwent breast ultrasound, the detection rate of breast nodules surged from 17.17% in 2019 to 42.26% in 2025, more than doubling in seven years. More worryingly, this rate is projected to exceed 50% by 2028. Anger, depression, anxiety… every negative emotion can burden the breast.

Against this backdrop, Ms. Liu from Shenzhen received her own “medical surprise” in early 2026.

Seven Years of Seeking Treatment:

From a Mother of Two to a “Nodule-Anxious Patient”The story dates back six to seven years. Ms. Liu had just given birth to her second child. Before she could fully recover from the joy, she suffered from acute mastitis. Although the inflammation subsided, it seemed to leave lasting “aftereffects.”

Severe breast pain before menstruation became a persistent nightmare every month. A later physical examination confirmed her fears: a 14×8 mm solid nodule in her left breast and a 7×3 mm cyst in her right breast.

BI-RADS category 3 means the malignant risk is less than 2%, and doctors usually recommend short-term follow-up or observation. But for Ms. Liu, the psychological burden of this “time bomb” was far heavier than the medical grading suggested.

Over the next six to seven years, she embarked on a long journey of seeking medical help. She visited many hospitals and tried various regimens: from conventional anti-inflammatory drugs to seemingly advanced stem cell therapy. She spent a lot of money and time, but the effects were unsatisfactory.

Treatment Dilemma:

When “Watchful Waiting” Becomes TormentMs. Liu’s experience reflects the dilemma of countless breast nodule patients. Currently, the mainstream clinical advice for breast nodules is regular re-examination. But “waiting” is often accompanied by anxiety: What if the nodule grows? What if it becomes malignant?

Current clinical management for breast nodules mainly includes regular follow-up, medication, and surgical intervention. However, these options have limitations for many patients:

· Regular follow-up: For low-risk benign nodules, clinical practice usually recommends re-examination every 3–6 months. During long-term follow-up, approximately 12.8% of nodules increase in volume, and 2.1% may change in nature. This “passive waiting” pattern easily triggers patient anxiety. A study by the School of Psychological and Cognitive Sciences, Peking University, showed that anxiety scores of patients on long-term follow-up were 41.3% higher than those of the general population.

· Medication: Existing drugs are mainly hormone-regulating agents, which only relieve symptoms such as breast pain and have limited effect on reducing nodule volume. They require continuous use for more than 6 months, and some patients may experience side effects such as menstrual irregularities.

· Surgical intervention: As a main method to clarify nodule nature and remove lesions, traditional surgery carries issues such as incision scars and mammary gland tissue damage, with a postoperative infection rate of about 2.3%–4.5%. For women of childbearing age, it may damage mammary ducts, leave scars, and even affect lactation function.

Not to mention patients who tried various conservative treatments with little success. They urgently need a new, non-destructive intervention.

Turning Point:

Meeting Inybrain tiNK Immune-Trained NK CellsThe turning point came on February 2, 2026. On that day, Ms. Liu received Inybrain tiNK immune-trained NK cell therapy, with a single intervention dose of 3 billion tiNK immune-trained NK cells.

After the intervention, subtle changes took place in Ms. Liu’s life. When her menstruation arrived, the severe breast pain that had plagued her for six to seven years did not appear at all. This long-lost relief made her hopeful about Inybrain tiNK immune-trained NK cell therapy for the first time.

On February 28, nearly one month after the intervention, Ms. Liu underwent another ultrasound examination with anxiety and expectation.

When the results came out, she could hardly believe her eyes:

The solid nodule in her left breast, originally 14×8 mm, shrank to 5×2 mm — an astonishing 91% reduction!

The cyst in her right breast also shrank from 7×3 mm to 5×3 mm, a reduction of 28.5%.

From a category 3 nodule to near disappearance — in just one month, with only one intervention.

“I didn’t expect one tiNK intervention to have such an effect,” Ms. Liu said excitedly. “It’s truly a surprise!”

Innovative Breakthrough of Inybrain tiNK Immune-Trained NK Cell Therapy

Inybrain tiNK immune-trained NK cells are NK cells activated by special factors and cultured through immune training. Training is a culture method that simulates NK cells under stress conditions, using high-intensity cytokines to enhance the killing ability of NK cells — like training a “new special forces soldier” into a “special forces champion,” enabling faster and more effective clearance of bacteria, viruses, senescent cells, and mutant cells in the body.

After entering the human body, tiNK immune-trained NK cells act on breast nodules through two pathways:

1. By recognizing low-expressed MHC-I molecules on the surface of nodule cells, they directly release perforin and granzyme to induce apoptosis of abnormal nodule cells. This process does not damage normal breast tissue; the intervention is mild, with no obvious side effects, fast recovery, and no impact on normal life and work.

2. By secreting various cytokines for immune regulation, they activate DC cells and T cells in the body to “fight” synergistically, rebuild the weakened immune defense line, and regulate immune balance. This not only reduces existing nodules but also strengthens the immune system’s ability to monitor and clear abnormal cells, fundamentally reducing the risk of nodule recurrence.

In terms of technical safety, Inybrain tiNK immune-trained NK cell therapy uses non-viral vectors and non-gene editing technology, avoiding safety risks caused by gene editing. It adopts feeder cell-free, serum-free, and full-factor culture, which greatly ensures the safety of cell application.

More importantly, the universal off-the-shelf feature of Inybrain tiNK immune-trained NK cells eliminates the need for “personalized customization” and allows allogeneic use, greatly shortening the treatment cycle and reducing treatment costs.

Cutting-Edge Technology

Opens a New Solution PathIn Ms. Liu’s case, 3 billion “trained” NK cells entered her body, likely precisely identifying and clearing cells causing inflammation and abnormal proliferation, and remodeling the immune microenvironment. They not only greatly reduced the solid nodule but also eliminated the premenstrual pain that had troubled her for years.

This treatment model, based on activating the body’s own immune function, breaks the traditional binary choice of “surgery or observation” and provides a new path for breast nodule management. Instead of passive waiting or traumatic resection, it solves problems proactively and gently by activating autoimmunity.

Ms. Liu’s case is just one example of Inybrain’s tiNK cell therapy exploration in non-oncological fields. Currently, Inybrain’s clinical pipeline not only covers solid tumors and hematological tumors but also shows great potential in autoimmune diseases, neurological diseases, and nodular diseases.

For millions of people suffering from breast nodules, thyroid nodules, pulmonary nodules, and other conditions like Ms. Liu, this early spring 2026 case may signal that the “third solution” — after surgery and medication — is accelerating toward us.

#BreastNodule #tiNK #NKCellTherapy #Immunotherapy #Inybrain #RADS3 #CellularTherapy #NoduleTreatment #Nonsurgical #ImmuneRegulation #medtourchina